Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials

Wen och kollegor gick igenom randomiserade kontrollerade studier som undersökte NMN:s effekt på fysisk prestationsförmåga och säkerhet. Översiktens uttalade syfte var att bedöma både effekten av och säkerhetsprofilen för NMN-tillskott. Across the included trials, NMN supplementation was associated with a non-significant improvement in physical strength and aerobic performance. Body composition and muscle mass were not significantly affected. The authors describe a dose-dependent and possibly time-dependent relationship, meaning higher doses and longer duration trials tended to show larger, though still not statistically significant, effects. On safety, no serious adverse events were observed, and doses up to 1200 mg per dag were well tolerated; reported side effects were determined to be independent of NMN supplementation. The authors explicitly note that the limited number of qualifying studies prevents a comprehensive conclusion about NMN's benefits. This review sits alongside the Zhang and Chen 2024 meta-analyses as a third independent voice reaching the same core verdict: NMN is safe at studied doses, reliably moves biomarkers, but has not yet demonstrated a clinically decisive functional benefit in adequately powered trials.

NMN supplementation is associated with a nonsignificant improvement in the physical strength and aerobic performance and is well tolerated with no serious adverse effects. However, body composition and muscle mass are not significantly affected. There is a dose-dependent and possibly time-dependent relationship with these benefits. However, the limited number of studies prevents a comprehensive conclusion on the benefits of NMN.